Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.75. Which is the better fit depends on your goals.
| ALNY | YMAG | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $15.98 |
52-Week Low | $278.09 | $11.00 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
YMAG trades at $11.81 with a 1.2% daily gain, showing modest momentum amid bearish technical signals. The ETF's weekly dividend strategy provides income but faces headwinds from its overall bearish technical rating and mixed oscillators. Recent news highlights YieldMax's consistent distribution announcements, though analyst coverage remains limited for this specialized fund-of-ETFs product.
The outlook remains cautious given the bearish technical setup and structural concerns about NAV decay in option-income strategies. While weekly distributions offer income appeal, the fund's performance depends heavily on volatility monetization capabilities during rangebound markets. Key risks include expense ratio drag and underperformance during strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
